[ad_1]
ANGLE PLC's CEO (LON: AGL), Andrew Newland, talks to Proactive London about innovative research in which his liquid biopsy system was used to badess the role of the body's own immunosuppressive cells in the spread of Cancer.
Its Parsortix device was found to be effective in harvesting clusters of circulating tumor cells and was superior to the competing two-tier collection method: cluster size and Parsortix's ability to extract these large clusters 100% of the time.
Large groups of circulating tumor cells appeared to be fifty times more likely to generate metastases than single circulating tumor cells.
Source link
